AlphAIalphai — Financial news for AI agents
Motley FoolNOV 63 min read$STVN

Stevanato (STVN) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Original reporting
Motley Fool · Motley Fool Transcribing, https://www.facebook.com/themotleyfool/
Published Nov 6, 2025, 3:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Stevanato (STVN) Q3 2025 Earnings Call Transcript — source image
Source · www.fool.com
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The transcript suggests stability but lacks catalysts for significant short-term price movements.

02

Market read

Limited immediate trading impact; primarily relevant for long-term investors and those with exposure to the company's sector.

03

What to watch

Potential upcoming product launches or macroeconomic developments could alter the outlook; these are not covered in the transcript.

Timing: short-term

Background

Stevanato's Q3 2025 earnings call provides insights into its financial health and strategic outlook.

Company-level read

Ticker impact

$STVNNeutralHigh confidence
Context

Primary focus of the transcript; high relevance for traders interested in this stock.

Expected impact

Potential for modest upward movement; long-term prospects remain stable.

Evidence & confidence

The transcript directly pertains to STVN, providing reliable insights for trading decisions.

Market effects

Sector

Limited; the company's performance does not significantly influence the broader sector.

Regional

Minimal; no regional shifts indicated.

Global

Negligible; the news is company-specific without global implications.

Counterpoint

What could challenge this read

Some investors might interpret the lack of positive surprises as a sign to wait for more definitive catalysts before increasing exposure.

Key entities

  • Company
    Stevanato Group S.p.A.

    A global provider of drug containment and delivery solutions.

Read at source← All news

Related articles

AUG 6
$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

yahoo.com6 min
AUG 5
$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

yahoo.com7 min
AUG 4
$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

SEC EDGAR 6-K2 min
AUG 4
$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.

finanznachrichten.de6 min
SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min